April 8, 2013
The U.S. Food and Drug Administration (FDA) has initiated several drug recalls during the past several weeks. Four major announcements have involved separate medications manufactured by different compounding centers, but have all been based on product contamination.
Last month, the FDA announced it had partnered with Clinical Specialties to implement a recall of injections of Avastin. Officials stated several patients had developed serious inner eye infections after receiving the injections. The recall was later expanded to include all medications the company produces since sterility could not be guaranteed.
The same day that initial recall was expanded, the FDA announced Med Prep Consulting, Inc. was recalling all of its compounded products because of mold contamination.
The FDA and Pallimed Solutions, Inc. later stated a similar recall was being conducted due to particulates in their compounded products. Then, on Friday, March 29, another company, Hospira, issued a statement saying it would be recalling injections of sodium chloride i because of brass particulates identified in certain lots of the injections.
The agency’s crackdown on compounding centers and their manufacturing standards often comes on the heels of numerous reports of a certain Drug Injury resulting from contamination during the manufacturing process.
The Colorado Personal Injury Lawyers with the McDivitt Law Firm encourage patients to carefully research and inspect medications before beginning a regimen prescribed by a doctor.